Belite Bio (BLTE) is positioned for growth following a successful Phase 3 DRAGON trial and NDA submission of tinlarebant, an oral therapy for Stargardt disease type 1. This oral treatment offers a competitive edge by enabling bilateral retinal therapy and potentially reducing the need for frequent eye injections. With nearly $799 million in cash and investments, BLTE is well-funded to support commercialization and further clinical trials, including the PHOENIX trial for geographic atrophy. However, the company's valuation depends heavily on regulatory approval and label conditions, which could impact its premium market value.
Taiwan's Taiex index reached a record intraday high of 48,601.53 driven by strong gains in the tech sector, especially semiconductor companies like TSMC, MediaTek, and Delta Electronics. This surge follows an AI-driven rally on Wall Street fueled by ...
China's lithium carbonate and spodumene spot prices fell significantly over the past month, influenced by the loss of license at CATL's Jianxiawo Mine, the country's largest lithium mine, which has returned to care and maintenance. Despite the price ...
Zcash (ZEC) price pulled back from a September peak near $1,590 to about $1,430, pausing after a strong rally. Institutional interest remains high, supported by Grayscale's Zcash ETF and a planned share split. The main issue is a debate over the Zcas...
Ethereum (ETH) has surpassed the $2500 resistance level, trading at $2,716.86 after a 5.7% rise in 24 hours, marking its strongest third quarter since 2016 with a 67.57% gain so far. This recovery follows two negative quarters in early 2026 where ETH...
Chinese President Xi Jinping is set to visit the U.S. from Wednesday to Friday, with several top American tech executives like Microsoft CEO Satya Nadella, Nvidia's Jensen Huang, and Apple's Tim Cook attending a key dinner in Washington, D.C. The Chi...
